- Home
- DUO vs PMCB Comparison
DUO vs PMCB Comparison
Compare DUO & PMCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DUO
- PMCB
- Stock Information
- Founded
- DUO 2011
- PMCB 1996
- Country
- DUO China
- PMCB United States
- Employees
- DUO N/A
- PMCB N/A
- Industry
- DUO Real Estate
- PMCB Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DUO Finance
- PMCB Health Care
- Exchange
- DUO Nasdaq
- PMCB Nasdaq
- Market Cap
- DUO 6.1M
- PMCB 6.7M
- IPO Year
- DUO 2019
- PMCB N/A
- Fundamental
- Price
- DUO $3.90
- PMCB N/A
- Analyst Decision
- DUO
- PMCB
- Analyst Count
- DUO 0
- PMCB 0
- Target Price
- DUO N/A
- PMCB N/A
- AVG Volume (30 Days)
- DUO 1.1M
- PMCB 118.1K
- Earning Date
- DUO 11-19-2025
- PMCB 09-15-2025
- Dividend Yield
- DUO N/A
- PMCB N/A
- EPS Growth
- DUO N/A
- PMCB N/A
- EPS
- DUO N/A
- PMCB 0.01
- Revenue
- DUO $56,189,313.00
- PMCB N/A
- Revenue This Year
- DUO N/A
- PMCB N/A
- Revenue Next Year
- DUO N/A
- PMCB N/A
- P/E Ratio
- DUO N/A
- PMCB $160.47
- Revenue Growth
- DUO 48.30
- PMCB N/A
- 52 Week Low
- DUO $1.24
- PMCB $0.80
- 52 Week High
- DUO $33.92
- PMCB $2.42
- Technical
- Relative Strength Index (RSI)
- DUO 55.00
- PMCB N/A
- Support Level
- DUO $3.03
- PMCB N/A
- Resistance Level
- DUO $3.78
- PMCB N/A
- Average True Range (ATR)
- DUO 0.37
- PMCB 0.00
- MACD
- DUO -0.07
- PMCB 0.00
- Stochastic Oscillator
- DUO 39.62
- PMCB 0.00
About DUO Fangdd Network Group Ltd.
Fangdd Network Group Ltd is an investment holding company. It is engaged in the provision of real estate information services through its online platform which also offers integrated marketing services for individual customers, real estate developers, and agents in China. Its SaaS-based solutions help real estate agents to connect with essential business resources, including customers, property listings, capital, and transaction data. The company generates the majority of its revenue from Base commission from transactions in China.
About PMCB PharmaCyte Biotech Inc.
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.